Pathologic Processes

Subtype terms (65)

More specific conditions that are subtypes of Pathologic Processes in the MeSH hierarchy.

• Acantholysis
• Arrhythmias, Cardiac

  133 drugs (99 approved, 34 experimental)

• Ascites

  95 drugs (54 approved, 41 experimental)

• Atrial Remodeling

  3 drugs approved

• Azotemia
• Cardiotoxicity

  72 drugs (62 approved, 10 experimental)

• Channelopathies
• Chromosome Aberrations

  35 drugs (31 approved, 4 experimental)

• Death

  27 drugs (18 approved, 9 experimental)

• Dehydration

  21 drugs (14 approved, 7 experimental)

• Delayed Graft Function

  28 drugs (20 approved, 8 experimental)

• Disease

  13 drugs (9 approved, 4 experimental)

• Disease Attributes

  3 drugs (2 approved, 1 experimental)

• Dysbiosis

  65 drugs (18 approved, 47 experimental)

• Emphysema

  45 drugs (33 approved, 12 experimental)

• Extravasation of Diagnostic and Therapeutic Materials

  4 drugs approved

• Femoracetabular Impingement

  17 drugs (12 approved, 5 experimental)

• Fibrosis

  257 drugs (172 approved, 85 experimental)

• Frailty

  50 drugs (26 approved, 24 experimental)

• Genomic Instability
• Gliosis
• Granuloma

  46 drugs (35 approved, 11 experimental)

• Granulomatosis, Orofacial

  1 drug approved

• Growth Disorders

  37 drugs (18 approved, 19 experimental)

• Hemolysis

  24 drugs (15 approved, 9 experimental)

• Hemorrhage

  227 drugs (152 approved, 75 experimental)

• Hyperammonemia

  7 drugs (5 approved, 2 experimental)

• Hyperamylasemia
• Hyperbilirubinemia

  13 drugs (7 approved, 6 experimental)

• Hyperplasia

  33 drugs (22 approved, 11 experimental)

• Hyperuricemia

  73 drugs (29 approved, 44 experimental)

• Hypovolemia

  20 drugs (13 approved, 7 experimental)

• Inflammation

  663 drugs (292 approved, 371 experimental)

• Intraoperative Complications

  16 drugs (14 approved, 2 experimental)

• Ischemia

  73 drugs (45 approved, 28 experimental)

• Leukoaraiosis
• Leukocytosis

  1 drug experimental

• Lithiasis
• Long Term Adverse Effects

  2 drugs (1 approved, 1 experimental)

• Malacoplakia
• Menstruation Disturbances

  40 drugs (28 approved, 12 experimental)

• Metaplasia

  2 drugs approved

• Muscle Weakness

  55 drugs (35 approved, 20 experimental)

• Myotoxicity
• Necrosis

  15 drugs (11 approved, 4 experimental)

• Neointima

  4 drugs approved

• Neoplastic Processes

  2 drugs (1 approved, 1 experimental)

• Nerve Degeneration

  23 drugs (14 approved, 9 experimental)

• Ochronosis
• Ossification, Heterotopic

  7 drugs (5 approved, 2 experimental)

• Ototoxicity

  15 drugs (10 approved, 5 experimental)

• Pigmentation Disorders

  8 drugs (7 approved, 1 experimental)

• Polydipsia
• Postoperative Complications

  258 drugs (192 approved, 66 experimental)

• Protein Aggregation, Pathological
• Respiratory Aspiration

  28 drugs (25 approved, 3 experimental)

• Retropneumoperitoneum
• Sclerosis

  106 drugs (56 approved, 50 experimental)

• Shock

  56 drugs (42 approved, 14 experimental)

• Teratogenesis
• Toxic Optic Neuropathy

  3 drugs (2 approved, 1 experimental)

• Ulcer

  100 drugs (54 approved, 46 experimental)

• Vascular Remodeling

  2 drugs approved

• Yang Deficiency

  2 drugs approved

• Yin Deficiency

  2 drugs approved

Drugs by status

Organizations